Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $17.39 USD
Change Today -0.43 / -2.41%
Volume 52.2K
As of 8:10 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

collegium pharmaceutical inc (COLL) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/26/15 - $17.98
52 Week Low
05/7/15 - $11.92
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

collegium pharmaceutical inc (COLL) Related Businessweek News

No Related Businessweek News Found

collegium pharmaceutical inc (COLL) Details

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, focuses on developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its lead product candidate is Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone, a prescribed opioid medication. The company is also developing COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-196, a morphine formulation for the treatment of pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for the treatment of attention deficit hyperactivity disorder. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Canton, Massachusetts.

23 Employees
Last Reported Date: 05/7/15
Founded in 2002

collegium pharmaceutical inc (COLL) Top Compensated Officers

Chief Executive Officer, President, Co-Founde...
Total Annual Compensation: $380.4K
Vice President of Corporate Development
Total Annual Compensation: $246.8K
Vice President of Clinical Development and He...
Total Annual Compensation: $288.9K
Compensation as of Fiscal Year 2014.

collegium pharmaceutical inc (COLL) Key Developments

Collegium Pharmaceutical, Inc. Files Amended and Restated Articles of Incorporation

On May 11, 2015, Collegium Pharmaceutical, Inc. filed amended and restated articles of incorporation (the Post-IPO Charter) with the State Corporation Commission of the Commonwealth of Virginia in connection with the closing of the Company's initial public offering of shares of its common stock (the IPO). The Company's board of directors and shareholders previously approved the Post-IPO Charter effective as of and contingent upon the closing of the IPO. The Post-IPO Charter became effective on May 12, 2015. The Post-IPO Charter amends and restates the company's previous articles of incorporation in their entirety to, among other things: (i) increase the authorized number of shares of common stock to 100,000,000 shares, (ii) eliminate all references to the previously existing series of preferred stock; (iii) authorize 5,000,000 shares of undesignated preferred stock that may be issued from time to time by the company's board of directors in one or more series; and (iv) provide for classification of the company's board of directors.

Collegium Pharmaceutical, Inc.(NasdaqGS:COLL) added to NASDAQ Composite Index

Collegium Pharmaceutical, Inc has been added to Nasdaq Composite Index

Collegium Pharmaceutical Mulls Acquisitions

Collegium Pharmaceutical, Inc., which has filed an IPO in the amount of $86.25 million, is looking for acquisitions. Regarding potential use of proceeds, the company stated, “the remainder, if any, to fund working capital and general corporate purposes, which may include litigation expenses (including expenses relating to the Purdue litigation) and the acquisition or licensing of product candidates, technologies, compounds, other assets or complementary businesses.”


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COLL:US $17.39 USD -0.43

COLL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for COLL.
View Industry Companies

Industry Analysis


Industry Average

Valuation COLL Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COLLEGIUM PHARMACEUTICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at